Aethlon Medical, Inc.

Aethlon Medical, Inc. is a medical technology company headquartered in San Diego, California, focused on developing products to diagnose and treat life and organ-threatening diseases. The company is committed to applying science, technology, and innovation to create accessible, high-quality medical products that positively impact patients' lives.

The company's primary product is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This technology is designed for the rapid depletion of cancer-promoting exosomes and circulating viruses from the human circulatory system. It targets critical unmet needs in both oncology and infectious diseases, with applications including the removal of viruses like COVID-19, Ebola, HIV, and Hepatitis C. The Hemopurifier has received "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies.

Led by CEO and CFO James B. Frakes, Aethlon Medical is actively advancing its clinical programs. As of March 2026, the company progressed to the final cohort of its oncology clinical trial in Australia for the Hemopurifier, following a positive safety review. In the same month, Aethlon Medical engaged Maxim Group LLC to evaluate strategic opportunities, indicating a focus on both operational development and potential corporate restructuring.